194 related articles for article (PubMed ID: 36395739)
1. Diminished arachidonate 5-lipoxygenase perturbs phase separation and transcriptional response of Runx2 to reverse pathological ventricular remodeling.
Xie S; Chen M; Fang W; Liu S; Wu Q; Liu C; Xing Y; Shi W; Xu M; Zhang M; Chen S; Zeng X; Wang S; Deng W; Tang Q
EBioMedicine; 2022 Dec; 86():104359. PubMed ID: 36395739
[TBL] [Abstract][Full Text] [Related]
2. Role of IgE-FcεR1 in Pathological Cardiac Remodeling and Dysfunction.
Zhao H; Yang H; Geng C; Chen Y; Pang J; Shu T; Zhao M; Tang Y; Li Z; Li B; Hou C; Song X; Wu A; Guo X; Chen S; Liu B; Yan C; Wang J
Circulation; 2021 Mar; 143(10):1014-1030. PubMed ID: 33305586
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling.
Zhou Q; Meng D; Li F; Zhang X; Liu L; Zhu Y; Liu S; Xu M; Deng J; Lei Z; Sluijter JPG; Xiao J
EBioMedicine; 2022 Nov; 85():104274. PubMed ID: 36182775
[TBL] [Abstract][Full Text] [Related]
4. OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes.
Wang M; Han X; Yu T; Wang M; Luo W; Zou C; Li X; Li G; Wu G; Wang Y; Liang G
Theranostics; 2023; 13(7):2263-2280. PubMed ID: 37153745
[No Abstract] [Full Text] [Related]
5. The valosin-containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload.
Zhou N; Ma B; Stoll S; Hays TT; Qiu H
Aging Cell; 2017 Oct; 16(5):1168-1179. PubMed ID: 28799247
[TBL] [Abstract][Full Text] [Related]
6. Arachidonate 5-lipoxygenase is essential for biosynthesis of specialized pro-resolving mediators and cardiac repair in heart failure.
Halade GV; Kain V; Hossain S; Parcha V; Limdi NA; Arora P
Am J Physiol Heart Circ Physiol; 2022 Oct; 323(4):H721-H737. PubMed ID: 36018758
[TBL] [Abstract][Full Text] [Related]
7. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity.
Hullmann JE; Grisanti LA; Makarewich CA; Gao E; Gold JI; Chuprun JK; Tilley DG; Houser SR; Koch WJ
Circ Res; 2014 Dec; 115(12):976-85. PubMed ID: 25332207
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling.
Vigil-Garcia M; Demkes CJ; Eding JEC; Versteeg D; de Ruiter H; Perini I; Kooijman L; Gladka MM; Asselbergs FW; Vink A; Harakalova M; Bossu A; van Veen TAB; Boogerd CJ; van Rooij E
Cardiovasc Res; 2021 May; 117(6):1532-1545. PubMed ID: 32717063
[TBL] [Abstract][Full Text] [Related]
9. Silencing Survivin: a Key Therapeutic Strategy for Cardiac Hypertrophy.
Kusmic C; Vizzoca A; Taranta M; Tedeschi L; Gherardini L; Pelosi G; Giannetti A; Tombelli S; Grimaldi S; Baldini F; Domenici C; Trivella MG; Cinti C
J Cardiovasc Transl Res; 2022 Apr; 15(2):391-407. PubMed ID: 34409583
[TBL] [Abstract][Full Text] [Related]
10. SENP1 Protects Against Pressure Overload-Induced Cardiac Remodeling and Dysfunction Via Inhibiting STAT3 Signaling.
Yang D; Fan D; Guo Z; Liu FY; Wang MY; An P; Yang Z; Tang QZ
J Am Heart Assoc; 2022 Nov; 11(22):e027004. PubMed ID: 36370010
[TBL] [Abstract][Full Text] [Related]
11. Targeting miR-30d reverses pathological cardiac hypertrophy.
Li J; Sha Z; Zhu X; Xu W; Yuan W; Yang T; Jin B; Yan Y; Chen R; Wang S; Yao J; Xu J; Wang Z; Li G; Das S; Yang L; Xiao J
EBioMedicine; 2022 Jul; 81():104108. PubMed ID: 35752105
[TBL] [Abstract][Full Text] [Related]
12. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Induced Mitogenic Factor Promotes Cardiac Hypertrophy via Calcium-Dependent and Hypoxia-Inducible Factor-1α Mechanisms.
Kumar S; Wang G; Liu W; Ding W; Dong M; Zheng N; Ye H; Liu J
Hypertension; 2018 Aug; 72(2):331-342. PubMed ID: 29891648
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA
Yu J; Yang Y; Xu Z; Lan C; Chen C; Li C; Chen Z; Yu C; Xia X; Liao Q; Jose PA; Zeng C; Wu G
Circ Heart Fail; 2020 Jan; 13(1):e006525. PubMed ID: 31957467
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of METRNL overexpression against pathological cardiac remodeling.
Cao H; Liao Y; Hong J
Gene; 2024 Apr; 901():148171. PubMed ID: 38242372
[TBL] [Abstract][Full Text] [Related]
16. Exercise-derived peptide protects against pathological cardiac remodeling.
Yin A; Yuan R; Xiao Q; Zhang W; Xu K; Yang X; Yang W; Xu L; Wang X; Zhuang F; Li Y; Cai Z; Sun Z; Zhou B; He B; Shen L
EBioMedicine; 2022 Aug; 82():104164. PubMed ID: 35843176
[TBL] [Abstract][Full Text] [Related]
17. ANGPTL8 is a negative regulator in pathological cardiac hypertrophy.
Hu L; Wei J; Zhang Y; Wang Z; Tang J; Tang J; Gao Y; Zhang X; Li Y; Liu Y; Ma S; Guo X; Zhang Q
Cell Death Dis; 2022 Jul; 13(7):621. PubMed ID: 35851270
[TBL] [Abstract][Full Text] [Related]
18. DEF6(differentially exprehomolog) exacerbates pathological cardiac hypertrophy via RAC1.
Sun Y; Xu C; Jiang Z; Jiang X
Cell Death Dis; 2023 Jul; 14(7):483. PubMed ID: 37524688
[TBL] [Abstract][Full Text] [Related]
19. Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling.
Sato T; Kadowaki A; Suzuki T; Ito H; Watanabe H; Imai Y; Kuba K
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634441
[TBL] [Abstract][Full Text] [Related]
20. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
Liu Q; Chen Y; Auger-Messier M; Molkentin JD
Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
